Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 18;5(2):253-257.
doi: 10.1002/jgh3.12480. eCollection 2021 Feb.

Hepatitis C direct-acting antiviral outcomes in patients 75 years and older

Parmvir Parmar  1   2 , Stephen D Shafran  3 , Sergio M Borgia  4 , Karen Doucette  3 , Curtis L Cooper  1   2
Affiliations

Hepatitis C direct-acting antiviral outcomes in patients 75 years and older

Parmvir Parmar et al. JGH Open. .

Abstract

Background and aim: Elderly patients with hepatitis C virus (HCV) infection have worse interferon-based treatment outcomes than young patients. Direct-acting antiviral (DAA) regimens have enabled the treatment of previously difficult-to-cure populations. There are few studies that specifically assess DAA treatment outcomes in patients over 75 years of age.

Methods: Design: This was a cohort study. Setting: The setting was three Canadian HCV specialty sites. Participants: Patients aged 75 years and older and treated with DAA without interferon were enrolled. Measurements: Patient demographics, liver fibrosis by transient elastography, treatment regimen, and treatment outcome data were collected.

Results: The mean age of 78 patients in our analysis was 78.6 years (SD 3.5; range: 75-88 years). The most common genotype was 1b (35%). The most frequently utilized regimens included sofosbuvir-velpatasvir (33%) and ledipasvir-sofosbuvir (32%). Ribavirin was included for 17% of recipients. Sustained virological response (SVR) was achieved in 94% of patients (69% of those receiving ribavirin and 98% of patients on ribavirin-free regimens). Ribavirin toxicity contributed to the lower SVR rates in ribavirin-exposed patients. Ribavirin dosage was decreased in three patients and ultimately discontinued in two of these patients. All treatment was discontinued in another two patients.

Conclusion: Ribavirin-free DAA therapy is safe and achieves SVR rates in older adults comparable to those described in the general population. RBV inclusion frequently results in complications, often leads to treatment modification or interruption, and does not improve SVR rates in those with advanced age.

Keywords: direct‐acting antivirals; elderly; hepatitis C; ribavirin; sustained virologic response.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Alvarez K, Smaldone A, Larson E. Burden of hepatitis C virus infection among older adults in long‐term care settings: a systematic review of the literature and meta‐analysis. Curr. Infect. Dis. Rep. 2016; 18: 13. - PMC - PubMed
    1. Huang C, Yu M. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin. Pharmacother. 2017; 18: 1867–74. - PubMed
    1. Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging. 2008; 25: 9–18. - PubMed
    1. Foster G, Asselah T, Kopecky‐Bromberg S et al Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019; 14: e0208506. - PMC - PubMed
    1. Huang C, Chuang W, Yu M. Chronic hepatitis C infection in the elderly. Kaohsiung J. Med. Sci. 2011; 27: 533–7. - PubMed

LinkOut - more resources